USPTO issues patent to Enveric titled ‘Multi-Substituent Psilocybin Derivatives’

Enveric Biosciences announced that, on March 5 the United States Patent and Trademark Office issued U.S. Patent No. 11,918,594, titled “Multi-Substituent Psilocybin Derivatives” and is further expected to issue, on March 19, 2024, U.S. Patent No. 11,931,338, titled “Nitrilated Psilocybin Derivatives”. The newly issued patent and soon to be issued patent provide composition of matter claim coverage on numerous potential drug candidates not previously publicly disclosed by Enveric, as well as to six compounds subject to the three recently announced Non-Binding Term Sheets that Enveric entered into with an undisclosed biotechnology company…”These developments further demonstrate and validate the value of opportunities presented by Enveric to potential licensees seeking to develop novel chemical entities into proprietary, patent protected products intended to address mental health disorders affecting millions of people globally.” While inviting drug development of its Psybrary collection of compounds by others with the potential of significant financial return, Enveric continues to focus on advancing its own lead programs, EB-002 and EB-003, to develop therapeutics for the treatment of specific mental health disorders and to maximize the impact of its investments.